Every listing you will find for FOXO4-DRI for sale describes roughly the same object: a small glass vial holding 10 mg of white lyophilised powder, sold for laboratory use, with a purity figure somewhere above 98%. The listings differ far less than the material behind them does, which is why reading the claim structure matters more than comparing storefronts.
Key takeaways
- The market has settled on one format for this compound: a single 10 mg lyophilised vial. There is no 5 mg or 30 mg tier to trade off, and no legitimate pre-mixed presentation.
- A purity percentage and a net content figure answer different questions. A vial can be 99.97% pure and still hold 8.30 mg where the label says 10 mg.
- Anything sold pre-dissolved should be treated as a red flag. Peptides are shipped lyophilised because solution is where they degrade.
- FOXO4-DRI is a senolytic with no anabolic activity and no hypertrophy data in any species. It is not a muscle-building product and no listing should imply otherwise.
- The compound has never been tested in a human trial, so every listing you see is selling research material on research terms.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
What FOXO4-DRI for sale actually gets you
FOXO4-DRI reached the research-supply market off the back of a single high-profile paper in 2017, and the product form has barely changed since. A survey of what is genuinely listed comes down to a short set of variants.
The standard offering is a 10 mg vial of lyophilised powder, sealed under a crimped cap, sold with a certificate of analysis and a research-use-only designation. This is the format Ascension stocks and the one nearly every serious supplier converges on. Ten milligrams is a convenient quantity for laboratory work and an awkward one for anything else, which is itself informative about who the product is built for.
Below that tier things get less trustworthy. Occasional listings advertise blends pairing FOXO4-DRI with other compounds, which makes the contribution of any single ingredient impossible to isolate and makes the certificate, if there is one, much harder to interpret. Others advertise pre-reconstituted solution or a pre-loaded delivery device. Those should stop you. Peptides are freeze-dried for shipping and storage precisely because degradation accelerates once a compound is in solution, and a supplier shipping it wet has either not thought about stability or is counting on you not to.
You will also meet the phrase "pharma grade". It has no regulatory meaning attached to a compound with no pharmaceutical approval anywhere. For FOXO4-DRI it is decoration.
Reading a listing claim by claim
The useful exercise is to take the claims a product page makes and ask, for each one, what document could possibly support it.
| Listing claim | What it would take to support it | How often that exists |
|---|---|---|
| "99%+ purity" | An HPLC chromatogram tied to your lot number | Sometimes, and it is checkable |
| "Third-party tested" | A named laboratory with a real address | Often absent, and unfalsifiable without the name |
| "10 mg per vial" | A measured net content figure, not the label | Rarely published, and it is the one that varies |
| "Verified identity" | LC-MS confirming the molecule, not just purity | Occasionally, and it is worth more than purity |
| "Endotoxin free" | An LAL screen on the specific batch | Batch-dependent, and frequently generalised |
| "Pharma grade" | Nothing. There is no approved product | Never, because the category does not exist here |
| "Research use only" | The vendor simply stating it | Always, and its absence is a serious warning |
The pattern in that table is that purity is the claim most often made and net content is the claim that most often differs from what a buyer assumes. Purity tells you what fraction of the material present is the intended molecule. It says nothing about how much material is present.
The number most listings do not show you
Ascension is unusual in publishing measured net content, and the numbers are the reason this article exists in the form it does.
Two laboratories tested two different batches. Kovera Labs certified batch 55-05260628 on 15 June 2026 at 99.411% purity with 11.41 mg of net content. MZ Biolabs analysed lot 55-01260229 on 10 January 2026 at 99.97% purity with 8.30 mg of net content. Both vials carried a 10 mg label.
That is a spread of roughly 37% in delivered peptide between two batches of the same product, sitting behind two excellent purity figures. Neither certificate is doing anything wrong. They are measuring different things, and only one of those things is the one buyers assume they are reading.
The reason this matters beyond bookkeeping is that any concentration you calculate from the label inherits the error. Reconstitute a vial you believe holds 10 mg into 2 mL of bacteriostatic water and you would write down 5 mg/mL. If the vial actually held 8.30 mg, the true figure is 4.15 mg/mL, and every volume drawn from it is roughly 17% short of intention. The peptide calculator does the arithmetic correctly, but it can only work from the number you give it.
There is a second, quieter point in those certificates. The June batch was screened for endotoxins and microbial growth and passed both. The January batch was not screened for either. Testing scope belongs to the batch, so a page saying "endotoxin tested" as though it described the product is overstating what the documents show. Ask for the report matching the lot you receive.
What the compound is, and what it is not
Since this is a body-composition site, the boundary is worth stating without hedging.
FOXO4-DRI is a D-retro-inverso peptide, meaning it is built from D-amino acids in reversed sequence, a construction chosen to resist the proteases that would otherwise degrade it quickly. Its purpose is to disrupt the interaction between the FOXO4 protein and p53, which in senescent cells causes p53 to be excluded from the nucleus and the cell to undergo apoptosis. Healthy cells are largely unaffected, which is what makes it selective. The mechanism was worked out in Baar and colleagues, Cell, 2017 and refined in later structural work.
None of that is anabolic. FOXO4-DRI does not touch myostatin, activin or follistatin signalling, does not stimulate protein synthesis, and has never been measured against a hypertrophy or strength endpoint in any organism. If your interest came from the muscle-growth peptide material, this is a different category of compound entirely, and the honest framing is tissue maintenance rather than growth.
It is also not a compound with a clean safety story. Senescent cells are not simply waste; they contribute to tumour suppression and wound healing, and removing them has costs. A 2023 report in Circulation found that eliminating senescent cells could promote pulmonary hypertension. There are no human trials of FOXO4-DRI at all, so nobody can tell you how that balance resolves in a person.
Frequently asked questions
What size vials of FOXO4-DRI are sold?
Effectively one: a 10 mg lyophilised vial. Unlike compounds sold across several strengths, there is no second tier to compare on price per milligram, so a listing offering unusual sizes is worth extra scrutiny rather than treating as a better deal.
Does a 99% purity claim mean the vial holds 10 mg?
No, and conflating the two is the most common mistake made with these listings. Purity describes what proportion of the material is the intended molecule. Net content describes how much material is there. Ascension's two published batches measured 11.41 mg and 8.30 mg while both testing above 99% pure.
Why is pre-mixed FOXO4-DRI a red flag?
Because peptides degrade faster in solution than as dry powder, which is why the entire market ships them lyophilised. A supplier offering pre-dissolved material is either indifferent to stability or is selling something whose potency at arrival cannot be assumed.
Is FOXO4-DRI sold as a muscle-building peptide?
It is sometimes marketed adjacent to that audience, which is misleading. It has no anabolic mechanism and no performance data in any species. The genuine reason a body-composition reader might follow it is that senescent-cell accumulation is one contributor to age-related muscle decline, and that remains a hypothesis rather than a demonstrated human result.